Combination of immuno-oncolytic virus drugs for enhancing systemic immune response and application thereof
AssigneeSichuan Oncocare Biopharmaceutical, Inc.
InventorLi YU
Life of this patent
Estimating the term…
Abstract
This disclosure provides the innovation of a group of flaviviruses carrying respective lymphocyte genes that results in targeting specific T cells of immune system to therapy solid cancers and provides strategies for using these oncolytic viruses to reduce or to avoid immune resistance to single virus treatment and thus increase efficiency against cancer.
Claims13
A combination of immuno-oncolytic virus drugs that carry immune gene fragment(s) derived from human to enhance a systemic immune response to malignancy, wherein therapeutic drugs comprise positive-sense single-stranded RNA (ssRNA) viruses with a plurality of different serotypes.
Dependencies are inferred from the claim text.